O	0	1	[
O	1	8	Chinese
O	9	13	HER2
O	14	22	positive
O	23	28	early
O	29	35	breast
O	36	42	cancer
B-intervention	43	54	trastuzumab
I-intervention	55	63	adjuvant
I-intervention	64	71	therapy
O	71	72	:
O	73	84	preliminary
O	85	93	outcomes
O	93	94	]
O	94	95	.

O	96	98	To
O	99	107	evaluate
O	108	111	the
O	112	120	efficacy
O	121	124	and
O	125	131	safety
O	132	134	of
O	135	136	1
O	136	137	-
O	137	141	year
O	142	150	adjuvant
O	151	162	trastuzumab
O	163	164	(
O	164	173	herceptin
O	173	174	)
O	175	181	versus
O	182	183	1
O	183	184	-
O	184	188	year
B-control	189	192	non
I-control	192	193	-
I-control	193	204	trastuzumab
I-control	205	216	observation
O	217	219	in
B-ethinicity	220	227	Chinese
B-eligibility	228	236	patients
I-eligibility	237	241	with
I-eligibility	242	246	HER2
I-eligibility	246	247	-
I-eligibility	247	255	positive
I-eligibility	256	261	early
I-eligibility	262	268	breast
I-eligibility	269	275	cancer
O	276	282	during
O	283	284	a
O	285	291	median
O	292	298	follow
O	298	299	-
O	299	301	up
O	302	304	of
O	305	306	1
O	307	311	year
O	311	312	.

O	313	316	The
O	317	321	HERA
O	322	327	trial
O	328	331	was
O	332	334	an
O	335	348	international
O	348	349	,
O	350	361	multicenter
O	361	362	,
O	363	373	randomized
O	373	374	,
O	375	379	open
O	379	380	-
O	380	385	label
O	385	386	,
O	387	392	phase
O	393	396	III
O	397	402	trial
O	403	412	comparing
O	413	422	treatment
O	423	427	with
O	428	439	trastuzumab
O	440	443	for
O	444	445	1
O	446	449	and
O	450	451	2
O	452	457	years
O	458	462	with
O	463	474	observation
O	475	480	after
O	481	489	standard
O	490	498	adjuvant
O	499	511	chemotherapy
O	511	512	,
O	513	525	radiotherapy
O	526	528	or
O	529	533	both
O	534	536	in
O	537	545	patients
O	546	550	with
O	551	555	HER2
O	555	556	-
O	556	564	positive
O	565	569	node
O	569	570	-
O	570	578	positive
O	579	581	or
O	582	586	high
O	586	587	-
O	587	591	risk
O	592	596	node
O	596	597	-
O	597	605	negative
O	606	611	early
O	612	618	breast
O	619	625	cancer
O	625	626	.

O	627	630	The
O	631	638	primary
O	639	647	endpoint
O	648	651	was
B-outcome-Measure	652	659	disease
I-outcome-Measure	659	660	-
I-outcome-Measure	660	664	free
I-outcome-Measure	665	673	survival
O	673	674	.

O	675	684	Secondary
O	685	688	end
O	689	695	points
O	696	704	included
B-outcome-Measure	705	715	recurrence
I-outcome-Measure	715	716	-
I-outcome-Measure	716	720	free
I-outcome-Measure	721	729	survival
O	729	730	,
B-outcome-Measure	731	738	distant
I-outcome-Measure	739	746	disease
I-outcome-Measure	746	747	-
I-outcome-Measure	747	751	free
I-outcome-Measure	752	760	survival
O	760	761	,
B-outcome-Measure	762	769	overall
I-outcome-Measure	770	778	survival
O	779	782	and
B-outcome-Measure	783	790	cardiac
I-outcome-Measure	791	797	safety
O	797	798	.

O	799	802	The
O	803	808	first
O	809	816	planned
O	817	824	interim
O	825	833	analysis
O	834	843	comparing
O	844	847	the
O	848	856	efficacy
O	857	860	and
O	861	867	safety
O	868	870	of
O	871	880	treatment
O	881	885	with
O	886	897	trastuzumab
O	898	901	for
O	902	903	1
O	904	908	year
O	909	915	versus
O	916	927	observation
O	928	932	were
O	933	942	completed
O	943	945	in
O	946	951	April
O	952	956	2005
O	956	957	.

O	958	962	Only
O	963	966	the
O	967	975	outcomes
O	976	978	of
O	979	988	recruited
O	989	996	Chinese
O	997	1005	patients
O	1006	1010	were
O	1011	1019	reported
O	1019	1020	.

O	1021	1022	A
O	1023	1028	total
O	1029	1031	of
B-total-participants	1032	1035	122
O	1036	1043	Chinese
O	1044	1052	patients
O	1053	1057	from
O	1058	1059	8
O	1060	1073	participating
O	1074	1081	centers
O	1082	1086	were
O	1087	1095	included
O	1096	1099	for
O	1100	1107	planned
O	1108	1115	interim
O	1116	1124	analysis
O	1124	1125	.

O	1126	1129	And
O	1130	1134	they
O	1135	1139	were
O	1140	1147	divided
O	1148	1152	into
O	1153	1164	trastuzumab
O	1165	1166	(
O	1166	1167	n
O	1168	1169	=
B-intervention-participants	1170	1172	68
O	1172	1173	)
O	1174	1177	and
O	1178	1189	observation
O	1190	1191	(
O	1191	1192	n
O	1193	1194	=
B-control-participants	1195	1197	54
O	1197	1198	)
O	1199	1205	groups
O	1205	1206	.

B-iv-bin-abs	1207	1212	Three
O	1213	1216	and
B-cv-bin-abs	1217	1222	eight
B-outcome	1223	1230	disease
I-outcome	1230	1231	-
I-outcome	1231	1235	free
I-outcome	1236	1244	survival
I-outcome	1245	1251	events
O	1252	1256	were
O	1257	1265	observed
O	1266	1268	in
O	1269	1272	the
O	1273	1284	trastuzumab
O	1285	1288	and
O	1289	1300	observation
O	1301	1307	groups
O	1308	1320	respectively
O	1320	1321	.

B-outcome	1322	1325	Two
I-outcome	1325	1326	-
I-outcome	1326	1330	year
I-outcome	1331	1338	disease
I-outcome	1338	1339	-
I-outcome	1339	1343	free
I-outcome	1344	1352	survival
I-outcome	1353	1358	rates
O	1359	1363	were
B-iv-bin-percent	1364	1366	92
I-iv-bin-percent	1366	1367	.
I-iv-bin-percent	1367	1368	9
I-iv-bin-percent	1368	1369	%
O	1370	1373	and
B-cv-bin-percent	1374	1376	81
I-cv-bin-percent	1376	1377	.
I-cv-bin-percent	1377	1378	4
I-cv-bin-percent	1378	1379	%
O	1380	1392	respectively
O	1393	1394	(
O	1394	1395	P
O	1396	1397	=
O	1398	1399	0
O	1399	1400	.
O	1400	1404	0489
O	1404	1405	)
O	1405	1406	;
B-outcome	1407	1408	2
I-outcome	1408	1409	-
I-outcome	1409	1413	year
I-outcome	1414	1424	recurrence
I-outcome	1424	1425	-
I-outcome	1425	1429	free
I-outcome	1430	1438	survival
O	1439	1442	and
B-outcome	1443	1450	distant
I-outcome	1451	1458	disease
I-outcome	1458	1459	-
I-outcome	1459	1463	free
I-outcome	1464	1473	survivals
O	1474	1478	were
B-iv-bin-percent	1479	1481	98
I-iv-bin-percent	1481	1482	.
I-iv-bin-percent	1482	1483	1
I-iv-bin-percent	1483	1484	%
O	1485	1487	vs
B-cv-bin-percent	1488	1490	81
I-cv-bin-percent	1490	1491	.
I-cv-bin-percent	1491	1492	4
I-cv-bin-percent	1492	1493	%
O	1494	1495	(
O	1495	1496	P
O	1497	1498	=
O	1499	1500	0
O	1500	1501	.
O	1501	1505	0064
O	1505	1506	)
O	1507	1510	and
B-iv-bin-percent	1511	1513	98
I-iv-bin-percent	1513	1514	.
I-iv-bin-percent	1514	1515	1
I-iv-bin-percent	1515	1516	%
O	1517	1519	vs
B-cv-bin-percent	1520	1522	83
I-cv-bin-percent	1522	1523	.
I-cv-bin-percent	1523	1524	3
I-cv-bin-percent	1524	1525	%
O	1526	1527	(
O	1527	1528	P
O	1529	1530	=
O	1531	1532	0
O	1532	1533	.
O	1533	1537	0117
O	1537	1538	)
O	1539	1551	respectively
O	1551	1552	.

O	1553	1564	Trastuzumab
O	1565	1568	was
O	1569	1578	generally
O	1579	1583	well
O	1583	1584	-
O	1584	1593	tolerated
O	1594	1598	with
O	1599	1600	a
O	1601	1607	decent
B-outcome	1608	1614	safety
I-outcome	1615	1622	profile
O	1622	1623	.

B-outcome	1624	1630	Severe
I-outcome	1631	1645	cardiotoxicity
O	1646	1649	was
O	1650	1653	not
O	1654	1662	observed
O	1662	1663	.

O	1664	1667	One
O	1667	1668	-
O	1668	1672	year
O	1673	1682	treatment
O	1683	1687	with
O	1688	1696	adjuvant
O	1697	1708	trastuzumab
O	1709	1717	improves
O	1718	1725	disease
O	1725	1726	-
O	1726	1730	free
O	1731	1739	survival
O	1739	1740	,
O	1741	1751	recurrence
O	1751	1752	-
O	1752	1756	free
O	1757	1765	survival
O	1766	1769	and
O	1770	1777	distant
O	1778	1785	disease
O	1785	1786	-
O	1786	1790	free
O	1791	1799	survival
O	1800	1802	in
O	1803	1810	Chinese
O	1811	1819	patients
O	1820	1824	with
O	1825	1829	HER2
O	1829	1830	-
O	1830	1838	positive
O	1839	1844	early
O	1845	1851	breast
O	1852	1858	cancer
O	1858	1859	.
